The presentation of results for Pharmacyclics Inc./Johnson & Johnson’s oral BTK inhibitor ibrutinib at the American Society of Hematology meeting spurred talk of a potential for a change in the standard of care for chronic lymphocytic leukemia, with potential to shift treatment away from a chemotherapy-based, all-intravenous approach toward targeted oral therapy.
Ibrutinib (PCI-32765) inhibits Bruton’s tyrosine kinase, a target at the heart of B-cell receptor signaling. Janssen Biotech licensed co-development rights...